866-997-4948(US-Canada Toll Free)

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018

Published By :

GBI Research

Published Date : Jun 2018

Category :

Pharmaceutical

No. of Pages : 344 Pages

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features dormant and discontinued products.

Diabetes refers to a group of metabolic diseases that result from defects in insulin secretion, insulin action or both of these. Type I diabetes is an autoimmune disease in which the pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the bodys immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. There are 263 products in development for this indication.

Type 2 diabetes, however, results from a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. Type 2 diabetes is more closely related to lifestyle choices such as diet and exercise habits than type I diabetes, with the majority of patients being overweight or obese. There are 574 products in development for this indication.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. There are 10 products in development for this indication.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. There are seven products in development for this indication.

Molecular targets acted on by products in development for diabetes and associated metabolic conditions include the insulin receptor, glucagon-like peptide 1 (GLP-1) receptor, glucagon receptor and glucokinase. Companies operating in this pipeline space include Novo Nordisk, Eli Lilly and Zealand Pharma

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 11
2 Introduction 12
2.1 Diabetes and Associated Metabolic Conditions Report Coverage 12
2.2 Type1 diabetes (Juvenile Diabetes) - Overview 12
2.3 Hyperinsulinemia - Overview 12
2.4 Hyperglycemia - Overview 12
3 Therapeutics Development 13
3.1 Type1 diabetes (Juvenile Diabetes) 13
3.2 Type2 diabetes 34
3.3 Hyperinsulinemia 71
3.4 Hyperglycemia 75
4 Therapeutics Assessment 78
4.1 Type1 diabetes (Juvenile Diabetes) 78
4.2 Type2 diabetes 89
4.3 Hyperinsulinemia 107
4.4 Hyperglycemia 114
5 Companies Involved in Therapeutics Development 119
5.1 Type1 diabetes (Juvenile Diabetes) 119
5.2 Type2 diabetes 168
5.3 Hyperinsulinemia 264
5.4 Hyperglycemia 266
6 Dormant Projects 267
6.1 Type1 diabetes (Juvenile Diabetes) 267
6.2 Type2 diabetes 277
6.3 Hyperinsulinemia 302
6.4 Hyperglycemia 302
7 Discontinued Products 303
7.1 Type1 diabetes (Juvenile Diabetes) 303
7.2 Type2 diabetes 305
7.3 Hyperglycemia 312
8 Product Development Milestones 313
8.1 Type1 diabetes (Juvenile Diabetes) 313
8.2 Type2 diabetes 324
8.3 Hyperinsulinemia 336
9 Appendix 343
9.1 Methodology 343
9.2 Coverage 343
9.3 Secondary Research 343
9.4 Primary Research 343
9.5 Expert Panel Validation 343
9.6 Contact Us 344
9.7 Disclaimer 344

1.1 List of Tables
Table 1: Number of Products under Development for Type1 diabetes (Juvenile Diabetes) 13
Table 2: Number of Products under Development by Companies, Type1 diabetes (Juvenile Diabetes) 15
Table 3: Number of Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes) 20
Table 4: Products under Development by Companies, Type1 diabetes (Juvenile Diabetes) 21
Table 5: Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes) 32
Table 6: Number of Products under Development for Type2 diabetes 34
Table 7: Number of Products under Development by Companies, Type2 diabetes 36
Table 8: Number of Products under Development by Universities/Institutes, Type2 diabetes 45
Table 9: Products under Development by Companies, Type2 diabetes 47
Table 10: Products under Development by Universities/Institutes, Type2 diabetes 67
Table 11: Number of Products under Development for Hyperinsulinemia 71
Table 12: Number of Products under Development by Companies, Hyperinsulinemia 73
Table 13: Number of Products under Development by Universities/Institutes, Hyperinsulinemia 74
Table 14: Products under Development by Companies, Hyperinsulinemia 74
Table 15: Products under Development by Universities/Institutes, Hyperinsulinemia 74
Table 16: Number of Products under Development for Hyperglycemia 75
Table 17: Number of Products under Development by Companies, Hyperglycemia 75
Table 18: Number of Products under Development by Universities/Institutes, Hyperglycemia 76
Table 19: Products under Development by Companies, Hyperglycemia 76
Table 20: Products under Development by Universities/Institutes, Hyperglycemia 77
Table 21: Number of Products by Stage and Target, Type1 diabetes (Juvenile Diabetes) 79
Table 22: Number of Products by Stage and Mechanism of Action, Type1 diabetes (Juvenile Diabetes) 82
Table 23: Number of Products by Stage and Route of Administration, Type1 diabetes (Juvenile Diabetes) 86
Table 24: Number of Products by Stage and Molecule Type, Type1 diabetes (Juvenile Diabetes) 88
Table 25: Number of Products by Stage and Target, Type2 diabetes 90
Table 26: Number of Products by Stage and Mechanism of Action, Type2 diabetes 96
Table 27: Number of Products by Stage and Route of Administration, Type2 diabetes 104
Table 28: Number of Products by Stage and Molecule Type, Type2 diabetes 106
Table 29: Number of Products by Stage and Target, Hyperinsulinemia 108
Table 30: Number of Products by Stage and Mechanism of Action, Hyperinsulinemia 110
Table 31: Number of Products by Stage and Route of Administration, Hyperinsulinemia 112
Table 32: Number of Products by Stage and Molecule Type, Hyperinsulinemia 113
Table 33: Number of Products by Stage and Target, Hyperglycemia 115
Table 34: Number of Products by Stage and Mechanism of Action, Hyperglycemia 116
Table 35: Number of Products by Stage and Route of Administration, Hyperglycemia 116
Table 36: Number of Products by Stage and Molecule Type, Hyperglycemia 118
Table 37: Type1 diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, 119
Table 38: Type1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, 120
Table 39: Type1 diabetes (Juvenile Diabetes) - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, 120
Table 40: Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, 120
Table 41: Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, 121
Table 42: Type1 diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, 121
Table 43: Type1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, 122
Table 44: Type1 diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, 122
Table 45: Type1 diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, 123
Table 46: Type1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, 123
Table 47: Type1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, 124
Table 48: Type1 diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, 125
Table 49: Type1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, 125
Table 50: Type1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, 125
Table 51: Type1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, 126
Table 52: Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, 127
Table 53: Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, 127
Table 54: Type1 diabetes (Juvenile Diabetes) - Pipeline by Biozeus, 127
Table 55: Type1 diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, 128
Table 56: Type1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, 128
Table 57: Type1 diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc, 128
Table 58: Type1 diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, 129
Table 59: Type1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, 129
Table 60: Type1 diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, 130

1.2 List of Figures
Figure 1: Number of Products under Development for Type1 diabetes (Juvenile Diabetes) 13
Figure 2: Number of Products under Development by Companies, Type1 diabetes (Juvenile Diabetes) 14
Figure 3: Number of Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes) 19
Figure 4: Number of Products under Development for Type2 diabetes 34
Figure 5: Number of Products under Development by Companies, Type2 diabetes 35
Figure 6: Number of Products under Development by Universities/Institutes, Type2 diabetes 44
Figure 7: Number of Products under Development for Hyperinsulinemia 71
Figure 8: Number of Products under Development by Companies, Hyperinsulinemia 72
Figure 9: Number of Products under Development for Hyperglycemia 75
Figure 10: Number of Products under Development by Universities/Institutes, Hyperglycemia 76
Figure 11: Number of Products by Top 10 Targets, Type1 diabetes (Juvenile Diabetes) 78
Figure 12: Number of Products by Stage and Top 10 Targets, Type1 diabetes (Juvenile Diabetes) 78
Figure 13: Number of Products by Top 10 Mechanism of Actions, Type1 diabetes (Juvenile Diabetes) 81
Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Type1 diabetes (Juvenile Diabetes) 81
Figure 15: Number of Products by Top 10 Routes of Administration, Type1 diabetes (Juvenile Diabetes) 85
Figure 16: Number of Products by Stage and Top 10 Routes of Administration, Type1 diabetes (Juvenile Diabetes) 85
Figure 17: Number of Products by Top 10 Molecule Types, Type1 diabetes (Juvenile Diabetes) 87
Figure 18: Number of Products by Stage and Top 10 Molecule Types, Type1 diabetes (Juvenile Diabetes) 87
Figure 19: Number of Products by Top 10 Targets, Type2 diabetes 89
Figure 20: Number of Products by Stage and Top 10 Targets, Type2 diabetes 89
Figure 21: Number of Products by Top 10 Mechanism of Actions, Type2 diabetes 95
Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Type2 diabetes 95
Figure 23: Number of Products by Top 10 Routes of Administration, Type2 diabetes 103
Figure 24: Number of Products by Stage and Top 10 Routes of Administration, Type2 diabetes 103
Figure 25: Number of Products by Top 10 Molecule Types, Type2 diabetes 105
Figure 26: Number of Products by Stage and Top 10 Molecule Types, Type2 diabetes 105
Figure 27: Number of Products by Targets, Hyperinsulinemia 107
Figure 28: Number of Products by Stage and Targets, Hyperinsulinemia 107
Figure 29: Number of Products by Mechanism of Actions, Hyperinsulinemia 109
Figure 30: Number of Products by Stage and Mechanism of Actions, Hyperinsulinemia 109
Figure 31: Number of Products by Routes of Administration, Hyperinsulinemia 111
Figure 32: Number of Products by Stage and Routes of Administration, Hyperinsulinemia 111
Figure 33: Number of Products by Molecule Types, Hyperinsulinemia 112
Figure 34: Number of Products by Stage and Molecule Types, Hyperinsulinemia 113
Figure 35: Number of Products by Targets, Hyperglycemia 114
Figure 36: Number of Products by Stage and Targets, Hyperglycemia 114
Figure 37: Number of Products by Mechanism of Actions, Hyperglycemia 115
Figure 38: Number of Products by Stage and Mechanism of Actions, Hyperglycemia 116
Figure 39: Number of Products by Molecule Types, Hyperglycemia 117
Figure 40: Number of Products by Stage and Molecule Types, Hyperglycemia 117

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *